Omeros Corporation (LON:0KBU)

Market Cap	310.34M
Revenue (ttm)	n/a
Net Income (ttm)	-125.26M
Shares Out	n/a
EPS (ttm)	-2.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	1,189
Open	6.57
Previous Close	n/a
Day's Range	6.57 - 6.64
52-Week Range	2.09 - 10.85
Beta	n/a
RSI	39.41
Earnings Date	Mar 31, 2025

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 202
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KBU

Financial Performance

Financial numbers in USD